版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Pharmaceutical Development with Focus on Paediatric formulations,WHO/FIP Training Workshop Hyatt Regency Hotel Sahar Airport Road Andheri East, Mumbai, India 28 April 2008 2 May 2008,Biopharmaceutical Classification System (BCS),Presented by: Lembit Rgo MD, PhD Contact details: Dr Lembit Rgo Coordin
2、ator, Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Geneva Switzerland E-Mail: ,Biopharmaceutical Classification System (BCS),Background What is a problem? What is WHO doing and planning to do? What resources are available? Conclusions,W
3、hat is the key for multisource (generic) pharmaceutical products?,New medicines applicant has to prove quality, safety and efficacy Multisource (generic) pharmaceutical products applicant has to prove quality, in case of safety and efficacy it refers to the originator product The key is THERAPEUTIC
4、INTERCHANGEABILITY It is assumed that if the concentration pattern in the blood is essentially the same then the safety and efficacy profile must be essentially the same,Therapeutic interchangeability: prerequisites,Constant and reproducible quality of MPPs Manufactured under GMP Compliance with all
5、 quality specifications Variations control No constant and reproducible quality, no need for proving interchangeability as it is meaningless (all batches different anyhow),Options to show therapeutic interchangeability of multisource pharmaceutical products (MPP),The in vitro approach refers to the
6、Biopharmaceutics Classification System (BCS),Drug substance classification according to the BCS. Active pharmaceutical ingredients (APIs) are classified into classes based on their aqueous solubility and permeability characteristics,In Vitro Approaches/Biowaiver options,The possibility of in vitro d
7、ocumentation of bioequivalence for certain medicines and dosage forms is specified in Section 9 of the WHO guidance document 1. If the drug substance in question is highly soluble and highly permeable (BCS class I) and is manufactured as an immediate release dosage form, exemption from an in vivo ph
8、armacokinetic bioequivalence study may be considered provided that relevant dissolution requirements are fulfilled.,Principles,The solubility is not meant to be the absolute solubility here. In contrast high solubility refers to the highest single unit dose to be completely soluble in 250 ml aqueous
9、 buffer medium within the pH range of 1.2 to 6.8 without any stability problems. As another related physicochemical characteristic high permeability should be demonstrated for the particular API demonstrating that the fraction dose absorbed amounts to at least 85 %. Accordingly, high permeability wo
10、uld stand for almost complete absorption of the compound in humans. Physicochemical measures needed for BCS classification purposes may be taken from sound literature. The WHO Model List of Essential Medicines has been reviewed based on the BCS concept and active compounds are classified accordingly
11、 in the appendix of respective WHO document 1.,A theoretical risk assessment is mandatory to minimize risk for falsely waiving a necessary in vivo study,Situations where BCS-based biowaivers are not applicable,Assessment of risks practical points,In practice some of the criteria listed in the table
12、for risk assessment are difficult to assess e.g., the meaning of critical use or bioavailability problems, and are probably not easy to be defined. However, published literature provides valuable examples of how to evaluate the applicability of the BCS based biowaiver approach (see biowaiver monogra
13、phs on the following slide).,Available resources: Biowaiver Monographs,Biowaiver monographs are worked out by group of well established scientists linked to FIP and published in Journal of Pharmaceutical Sciences These can be useful scientific material for manufacturers when considering applications
14、 for biowaiver based on BCS The monographs as such have no regulatory authority decisions will be made by regulators who may or may not accept biowaiver depending on their national legislation and requirements,Biowaiver monographs published,Stosik A.G., Junginger H.E., Kopp S., Midha K.K., Shah V.P.
15、, Stavchansky S., Dressman J.B., Barends D.M.: Biowaiver monographs for immediate release solid oral dosage forms: metoclopramide hydrochloride. J Pharm Sci Feb 12 (2008) Becker C., Dressman J.B., Amidon G.L, Junginger H.E., Kopp S., Midha K.K., Shah V.P., Stavchansky S., Barends D.M.: Biowaiver mon
16、ographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci Feb 12 (2008) Becker C., Dressman J.B., Amidon G.L, Junginger H.E., Kopp S., Midha K.K., Shah V.P., Stavchansky S., Barends D.M.: Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochl
17、oride. J Pharm Sci Aug 21 (2007) Becker C., Dressman J.B., Amidon G.L, Junginger H.E., Kopp S., Midha K.K., Shah V.P., Stavchansky S., Barends D.M.:Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. J Pharm Sci 96 (2007) 522-31,WHO Guidance (1),The in vitro dissolution in
18、vestigations including experimental conditions and characteristics are outlined in Section 9 of the WHO guideline 1. It is of utmost importance to note that it is not sufficient to demonstrate the in vitro dissolution characteristics for the particular multisource product, but to ensure the similari
19、ty of dissolution profiles between the test and comparator products 1.,WHO guidance (2),The WHO guidance in basic aspects is similar to the US FDA guidance on the biowaiver approach (August 2000) In addition, the current scientific discussions in terms of so called biowaiver extensions are also cons
20、idered. Accordingly, BCS based biowaivers may be acceptable for drugs containing BCS class 2 and 3 drug substances manufactured as immediate release dosage forms. As an example, a biowaiver may be possible for BCS class 3 drug products that are very rapidly (i.e. at least 85 % dissolution within 15
21、min in all required media) dissolving. The relevant dissolution criteria are outlined in section 9.2.1 of the WHO guideline 1.,Regulators guidance for industry,US FDA relevant to biowaiver guidelines: /cder/Guidance/3618fnl.pdf,Conclusions,Biowaiver concept is a developing concept and new
22、 guidance documents and scientific data are appearing Proper comparator products are also crucial for biowaiver Regulatory acceptance and practice of biowaivers needs to catch up the concept development WHO will soon issue more practical implementation guidelines for PQ programme WHO PQ programme st
23、arts accepting biowaivers, as appropriate,Some useful references,(1) Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report. Geneva, World Heal
24、th Organization, 2006, WHO Technical Report Series, No. 937, Annex 7: 347-390. (2) van Faassen F., Vromans H. et al. Biowaivers for oral immediate-release products: implications of linear pharmacokinetics. Clin Pharmacokinet 43 (2004) 1117. (3) Note to Applicants on the Choice of Comparator Products for the Prequalification Project. Located on the World Health Organization (WHO) Prequalification of Medicines web site, Guidance on selection of comparator product. Web page: /pq/ (4) Shah,
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 高考英语二轮复习语法突破专题3介词和介词短语市赛课公开课一等奖省名师获奖课件
- 八年级语文上册第6课最后一课省公开课一等奖新名师获奖课件
- 英文摘要写作1市公开课一等奖省赛课微课金奖课件
- 《书愤》22522省公开课一等奖全国示范课微课金奖课件
- 友谊的小船主题班会省公开课一等奖全国示范课微课金奖课件
- 立体几何总复习总结市公开课一等奖省赛课微课金奖课件
- 房地产合同注意事项
- 班主任技能大赛校长总结讲话稿2篇
- 写作如何突出中心市公开课一等奖省赛课微课金奖课件
- 定量分析中常用的分离方法
- 再好的香水也斗不过韭菜合子阅读答案-记叙文阅读及答案
- 第20课 第一次工业革命(教学设计) 部编版历史与社会九年级上册
- 冷水机组行业报告
- 财税行业产品运营分析
- 《发热量测定方法》课件
- 网红直播商业计划书
- 施工企业重大隐患整改制度范本
- 战略群体分析
- 催收策略及催收方案
- 《回收废电池》教学设计
- 认知症培训课件
评论
0/150
提交评论